Short‐course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy
Allergy2023Vol. 78(10), pp. 2756–2766
Citations Over TimeTop 10% of 2023 papers
Pieter‐Jan de Kam, Stefan Zielen, Jonathan A. Bernstein, Uwe Berger, Markus Berger, Mandy Cuevas, David Cypcar, A. Fuhr‐Horst, William A. Greisner, M Jandl, Silke Laßmann, Margitta Worm, Jonathan Matz, Emanuele Sher, Claire Smith, Gary C. Steven, Ralph Mösges, Mohamed H. Shamji, L. DuBuske, Federica Borghese, Kemi Oluwayi, T. Zwingers, M. Seybold, Ollie Armfield, Matthew D. Heath, Simon Hewings, Matthias Krämer, Murray Skinner
Abstract
This trial demonstrated a clinically relevant and statistically significant efficacy response to PQ Grass. Unprecedented effect sizes were reached for grass allergy of up to ≈40% compared to placebo for CSMS after only six PQ Grass injections. Both PQ Grass regimens were considered equally safe and well-tolerated. Based on enhanced efficacy profile extended regime will be progressed to the pivotal Phase III trial.
Related Papers
- → A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia(2002)434 cited
- → Gender Differences in Placebo Analgesia: Event-Related Potentials and Emotional Modulation(2011)116 cited
- → Conditioned Placebo Analgesia Persists When Subjects Know They Are Receiving a Placebo(2015)116 cited
- → Μελέτη της πολυπαραγοντικής αναλγησίας στο μετεγχειρητικό πόνο μετά από λαπαροσκοπική χολοκυστεκτομή(2014)
- → (404) Use of a placebo run-in in clinical trials in patients with FM does not impact the response to pregabalin(2015)